Table 3.

Adverse event analysis between the hMSC therapy group and the control group.

AE	Study	RR and 95% CI	P
Upper respiratory infection	2 [12, 13]	RR (0.80), 95% CI (0.34-1.87)	0.60
Diarrhea	2 [12, 13]	RR (0.81), 95% CI (0.42-1.57)	0.53
Constipation	2 [12, 13]	RR (0.59), 95% CI (0.13-2.62)	0.59